LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems

Lymphocyte activation gene-3 (LAG-3) is a cell-surface molecule with diverse biologic effects on T cell function. We recently showed that LAG-3 signaling is important in CD4+ regulatory T cell suppression of autoimmune responses. Here, we demonstrate that LAG-3 maintains tolerance to self and tumor...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of clinical investigation 2007-11, Vol.117 (11), p.3383-3392
Main Authors: Grosso, Joseph F, Kelleher, Cristin C, Harris, Timothy J, Maris, Charles H, Hipkiss, Edward L, De Marzo, Angelo, Anders, Robert, Netto, George, Getnet, Derese, Bruno, Tullia C, Goldberg, Monica V, Pardoll, Drew M, Drake, Charles G
Format: Article
Language:English
Subjects:
Adoptive Transfer
Animals
Antigens, CD - genetics
Antigens, CD - metabolism
CD8-Positive T-Lymphocytes - cytology
CD8-Positive T-Lymphocytes - immunology
Cell Line
Cell Proliferation
Humans
Immune Tolerance - immunology
Lymphocyte Activation
Male
Mice
Mice, Inbred C57BL
Self Tolerance - immunology
T-Lymphocyte Subsets - cytology
T-Lymphocyte Subsets - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lymphocyte activation gene-3 (LAG-3) is a cell-surface molecule with diverse biologic effects on T cell function. We recently showed that LAG-3 signaling is important in CD4+ regulatory T cell suppression of autoimmune responses. Here, we demonstrate that LAG-3 maintains tolerance to self and tumor antigens via direct effects on CD8+ T cells using 2 murine systems. Naive CD8+ T cells express low levels of LAG-3, and expression increases upon antigen stimulation. Our data show increased levels of LAG-3 protein on antigen-specific CD8+ T cells within antigen-expressing organs or tumors. In vivo antibody blockade of LAG-3 or genetic ablation of the Lag-3 gene resulted in increased accumulation and effector function of antigen-specific CD8+ T cells within organs and tumors that express their cognate antigen. Most notably, combining LAG-3 blockade with specific antitumor vaccination resulted in a significant increase in activated CD8+ T cells in the tumor and disruption of the tumor parenchyma. A major component of this effect was CD4 independent and required LAG-3 expression by CD8+ T cells. Taken together, these data demonstrate a direct role for LAG-3 on CD8+ T cells and suggest that LAG-3 blockade may be a potential cancer treatment.
ISSN:0021-9738
DOI:10.1172/JCI31184